Remote rehabilitation for people receiving CAR-T cell therapy
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | University of Utah Academic / other |
| Drugs / interventions | CAR-T, CAR T, CART, chemotherapy |
| Locations | 1 site (Salt Lake City, Utah) |
| Trial ID | NCT07390071 on ClinicalTrials.gov |
What this trial studies
The program uses a web-based care portal and a Home Automated Telemanagement (HAT) patient unit to deliver individualized exercise and nutrition plans alongside behavioral counseling and education. Patients complete guided touch-screen sessions at home while the cloud-based Internet-of-Things system collects cardiovascular and performance data in real time. A validated AI-driven algorithm estimates exertion level to support exercise safety and tailor intensity, and clinicians monitor progress remotely through the portal. This pilot feasibility project will measure effects on disease-specific quality of life, functional ability, and symptom burden in patients around the time of CAR-T therapy.
Who should consider this trial
Good fit: Adults over 21 with confirmed lymphoma or multiple myeloma who plan to receive a commercial FDA-approved CAR-T therapy at least four weeks after enrollment, have ECOG performance status 0–2, and have access to a working telephone or cell phone are ideal candidates.
Not a fit: Patients with unstable angina or recent myocardial infarction, uncontrolled hypertension, pacemakers, painful or unstable bony metastases or recent fractures, those already in a regular exercise rehabilitation program, planning to relocate within six months, or enrolled in another clinical trial are excluded and may not benefit.
Why it matters
Potential benefit: If successful, the program could help patients maintain or improve physical function, reduce symptoms and fatigue, and preserve quality of life during and after CAR-T therapy while reducing the need for frequent clinic visits.
How similar studies have performed: Exercise and telehealth interventions have improved quality of life and reduced fatigue in other cancer populations, but delivering multimodal telerehabilitation specifically for patients undergoing CAR-T therapy is a novel, early-stage approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>21 * confirmed diagnosis of lymphoma or myeloma * commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Access to a working telephone line in their home or a cell phone. Exclusion Criteria: * have unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures; * are engaged in a regular exercise rehabilitation program; * have relocation plans within next 6 months; * participate in another clinical trial.
Where this trial is running
Salt Lake City, Utah
- Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Principal investigator: Douglas Sborov, MD, MS — Huntsman Cancer Institute/ University of Utah
- Study coordinator: Aileen Gabriel
- Email: aileen.gabriel@utah.edu
- Phone: 801-585-3229
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.